PULMONARY ARTERIAL HYPERTENSION (PAH) · White paper
Pulmonary Arterial Hypertension (PAH) Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About pulmonary arterial hypertension (pah) — and why its trials are hard
Pulmonary arterial hypertension (PAH, WHO Group 1) is a progressive vasculopathy of the small pulmonary arteries that raises pulmonary vascular resistance, imposes afterload on the right ventricle, and ultimately causes right heart failure and death. Modern therapy targets three established pathways: the endothelin pathway (endothelin receptor antagonists bosentan, ambrisentan, macitentan), the nitric oxide-cGMP pathway (PDE5 inhibitors sildenafil and tadalafil, and the soluble guanylate cyclase stimulator riociguat), and the prostacyclin pathway (epoprostenol, treprostinil, and the oral IP-receptor agonist selexipag). A defining evolution in PAH drug development has been the shift in pivotal endpoints from the short-term 6-minute walk distance (6MWD) toward long-term, event-driven morbidity/mortality composites and time-to-clinical-worsening, exemplified by SERAPHIN (macitentan) and GRIPHON (selexipag). More recently, sotatercept (Winrevair), a first-in-class activin signaling inhibitor, was approved in 2024 based on the STELLAR trial. Endpoint challenges include the modest sensitivity of 6MWD in already-treated patients, the large sample sizes and long follow-up needed for event-driven trials, and increasing use of risk-stratification tools and hemodynamic/biomarker measures.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Bosentan (Tracleer) | 2001 | PAH WHO FC II-IV (dual endothelin receptor antagonist) | BREATHE-1 | 6-minute walk distance (6MWD) | Placebo-corrected 6MWD improvement ~44 m at 16 weeks |
| Sildenafil (Revatio) | 2005 | PAH (PDE5 inhibitor) | SUPER-1 | 6-minute walk distance (6MWD) | Placebo-corrected 6MWD improvement ~45 m at 12 weeks (20 mg TID) |
| Macitentan (Opsumit) | 2013 | PAH (endothelin receptor antagonist) | SERAPHIN | First morbidity/mortality event (long-term event-driven composite) | Reduced risk of morbidity/mortality event by ~45% (HR ~0.55, 10 mg) |
| Riociguat (Adempas) | 2013 | PAH and inoperable/persistent CTEPH (soluble guanylate cyclase stimulator) | PATENT-1 | 6-minute walk distance (6MWD) | Placebo-corrected 6MWD improvement ~36 m at 12 weeks |
| Selexipag (Uptravi) | 2015 | PAH (oral prostacyclin IP-receptor agonist) | GRIPHON | Morbidity/mortality composite (event-driven) | Reduced risk of primary composite event by ~40% (HR ~0.60) vs placebo |
| Sotatercept (Winrevair) | 2024 | PAH WHO Group 1, added to background therapy (activin signaling inhibitor) | STELLAR | 6MWD at Week 24; clinical worsening | 6MWD improved ~41 m vs placebo; markedly reduced risk of death/clinical-worsening events |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in pulmonary arterial hypertension (pah) development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Imatinib — IMPRES (NCT00902174) | Improved 6MWD and hemodynamics but development for PAH was not pursued | High rate of serious adverse events and discontinuations, including subdural hematomas (notably with anticoagulation) |
| Bardoxolone methyl — CATALYST (CTD-PAH) | Program in connective-tissue-disease-associated PAH terminated without demonstrated benefit | Efficacy and prior safety signals (fluid overload seen in earlier bardoxolone renal trials) in a difficult population |
| Ubenimex — LIBERTY | Failed to meet primary endpoint (pulmonary vascular resistance and 6MWD) | Insufficient effect of leukotriene A4 hydrolase inhibition on established PAH |
Choosing the right endpoint
Primary endpoints that matter in pulmonary arterial hypertension (pah) trials
- Morbidity/mortality composite (time to first event) — The modern regulatory-preferred primary endpoint (SERAPHIN, GRIPHON); event-driven and long-term but requires large samples and extended follow-up
- 6-minute walk distance (6MWD) — Historical primary endpoint; simple and reproducible but has a ceiling effect and modest sensitivity in already-treated patients
- WHO/NYHA functional class — Categorical measure of symptom burden and prognosis; coarse but clinically meaningful and used in risk stratification
- Hemodynamics (pulmonary vascular resistance, mPAP, cardiac output) — Objective right-heart-catheter measures of disease severity and drug effect; invasive, so used at defined assessment points
- NT-proBNP and multiparameter risk score (e.g. REVEAL) — Biomarker and composite risk tools increasingly used as secondary endpoints and enrichment/stratification measures
How iNGENū runs pulmonary arterial hypertension (pah) trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Pulmonary Arterial Hypertension (PAH) clinical trials — FAQs
Why did PAH trials move away from the 6-minute walk distance?
What are the main drug classes approved for PAH?
What is significant about sotatercept (Winrevair)?
Ready to discuss your pulmonary arterial hypertension (pah) trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal